<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03977415</url>
  </required_header>
  <id_info>
    <org_study_id>HS-3140</org_study_id>
    <nct_id>NCT03977415</nct_id>
  </id_info>
  <brief_title>Interstitial Lung Disease in Early Rheumatoid Arthritis</brief_title>
  <acronym>ILD-Early RA</acronym>
  <official_title>Interstitial Lung Disease in Early Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Jewish Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how interstitial lung disease can be predicted over
      time in early rheumatoid arthritis. The investigators will study blood and phlegm samples
      from participants, along with quality of life questionnaires to determine if and how the
      presence of ILD may impact the participants quality of life over time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participation involves 5 study visits over an 18 month timeframe. During each of these
      visits, a recent medical history and physical exam will take place, blood and phlegm will be
      collected, quality of life questionnaires will be administered, and a CT-scan of the chest
      and pulmonary function testing may be performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in anti-CCP antibody test to identify the presence or development of RA in patients with or without ILD</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lung antigen targets in RA-ILD using induced sputum</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline for Leicester Cough questionnaire-Acute (LCQ_Acute)</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline for Short Form (SF_36) questionnaire</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline for UCSD Medical Center Pulmonary Rehabilitations Program Shortness-of-Breath questionnaire</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline for Multi-Dimensional Health Assessment questionnaire (MDHAQ)</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Interstitial Lung Disease</condition>
  <arm_group>
    <arm_group_label>RA with no ILD</arm_group_label>
    <description>Subjects diagnosed with RA less then 2 years and without a diagnosis of ILD, will complete 5 in-person study visits. Visits will be performed every 6 months for 18 months.
Study Assessments Include:
Medical history and Physical exams
Quality of Life Questionnaires
Collection of Sputum and Blood
Radiology (HRCT)
Lung Function Test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RA with ILD</arm_group_label>
    <description>Patients diagnosed with RA less than 2 years, and clinically diagnosed with interstitial lung disease (ILD), will complete 5 in-person study visits. Visits will be performed every 6 months for 18 months.
Study Assessments Include:
Medical history and Physical exams
Quality of Life Questionnaires
Collection of Sputum and Blood
Radiology (HRCT)
Lung Function Test
Spirometry</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum biomarker and cell collection
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects are selected for participation in the study because they have an active diagnosis
        of rheumatoid arthritis and are at risk fro the development of lung disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 - 90 years

          2. Diagnosis of &quot;early RA&quot; with or without ILD as defined by ACR/EULAR 2010 criteria and
             confirmed by a member of the ILD or Rheumatology programs at National Jewish Health
             (NJH)

          3. Able to read, speak, and understand English

          4. Able and willing to perform all study related tasks, including returning to NJH every
             6 months for an 18 month period of time

        Exclusion Criteria:

          1. Subjects who do not meet all inclusion criteria

          2. Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Solomon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Faduma Ahmed, MPH</last_name>
    <phone>303-398-1285</phone>
    <email>ahmedf@NJHealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jami Henriksen</last_name>
    <phone>303-398-1996</phone>
    <email>henriksenj@njhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faduma Ahmed</last_name>
      <phone>303-398-1285</phone>
      <email>ahmedf@NJHealth.org</email>
    </contact>
    <investigator>
      <last_name>Kristen M Demoruelle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Mohning, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>July 26, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>June 5, 2019</last_update_submitted>
  <last_update_submitted_qc>June 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interstitial Lung Disease</keyword>
  <keyword>ILD</keyword>
  <keyword>Pulmonary Fibrosis</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>RA</keyword>
  <keyword>Rheumatology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

